Evidence map›Paper›PMID 33266022›Full record

Trial reportNutrients2020

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab.

Mia Bendix, Anders Dige, Søren Peter Jørgensen, Jens Frederik Dahlerup, Bo Martin Bibby, Bent Deleuran, Jørgen Agnholt

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Vitamin D for the treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mia BendixDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Anders DigeDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Søren Peter JørgensenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Jens Frederik DahlerupDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0002-1587-7636
Bo Martin BibbyDepartment of Public Health-Department of Biostatistics, Aarhus University, 8000 Aarhus, Denmark.
Bent DeleuranDepartment of Rheumatology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Jørgen AgnholtDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Aarhus University Hospital · DKAarhus University · DK

Funding

Beckett-Fonden no grant numberCentral Danish Region research foundation A1870Civilingeniør Frode V. Nyegaard og Hustrus Fond no grant numberColitis-Crohn Foreningen no grant number
6 · The paper itself

Abstract

backgroundVitamin D treatment may reduce Crohn's disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/- infliximab modulated the mucosal cytokine expression in active CD.

methodsForty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6.

resultsHigh-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab.

conclusionsHigh-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34.

Indexed as

AdolescentAdultAgedAged, 80 and overC-Reactive ProteinCrohn DiseaseDose-Response Relationship, DrugDouble-Blind MethodGene Expression RegulationHumansInfliximabInterferon-gammaInterleukin-10Interleukin-17Leukocyte L1 Antigen ComplexMiddle AgedC-Reactive ProteinIL10 protein, humanIL17A protein, humanInfliximabInterferon-gammaInterleukin-10Interleukin-17Leukocyte L1 Antigen ComplexVitamin DVitaminsCrohn’s diseaseinfliximabvitamin D treatment

Identifiers

PMID33266022
PMCPMC7759913
OpenAlexW3107974556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.